The utility of multiparametric seven‐color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples

Álvarez, Beatriz Carrasquer; Massó, Pilar; González, Fernando; Conejo, Luz; Velasco, Diego; Alonso, Juan-Manuel; Villarrubia, Jesús; Cava, Fernando; Llamas, Pilar

doi:10.1002/cyto.b.21227

Cited by 9 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BCL2 was frequently positive by flow cytometry in D/THL, but was most strongly expressed within the BCL2 + /MYC + cases compared to the MYC + /BCL6 + and MYC + /BCL2 + /BCL6 + cases. This finding confirms the prior observations that MYC + /BCL6 + cases are less frequently BCL2 positive by immunohistochemistry ( 8,14 ), and that strong flow cytometric expression of BCL2 may be helpful in the correct clinicopathologic context to identify cases to assess for a BCL2 gene rearrangement ( 20 ). In addition, we confirm that aberrant underexpression of CD45, CD19, and/or CD20 is seen in a subset of D/THL, which generally falls within the spectrum previously reported in the literature ( Table 4 ) and does not significantly vary by genetic subtype.…”

Section: Discussionsupporting

confidence: 90%

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma

Roth

Gillespie-Twardy²,

Marks³

et al. 2016

oncol res

View full text Add to dashboard Cite

"Double" or "triple" hit lymphomas (D/THL) with recurrent translocations involving MYC/8q24 and BCL2/18q21 and/or BCL6/3q27 are characterized by a poor prognosis, but their identification is hampered by the clinicopathologic overlap with other disease categories. Cases with circulating blastic-appearing cells may initially cause concern for lymphoblastic leukemia a diagnostic dilemma, which has not been well studied. There is only limited literature regarding the flow cytometric (FC) D/THL phenotype and its clinical correlates. The FC features of 20 D/THL (11 BCL2(+)/MYC(+), 5 BCL6(+)/MYC(+), 4 BCL2(+)/BCL6(+)/MYC(+)) were evaluated, compared to 20 B-lymphoblastic leukemias (B-LBL), and correlated with overall survival. Most (89%, 17/19) D/THL were CD10(+), 47% (9/19) lacked surface light chain, and a significant subset underexpressed CD45 (47%, 9/19), CD20 (42% 8/19), and/or CD19 (39%, 7/18), which did not vary by genetic subgroup. Compared to B-LBL, D/THL less frequently underexpressed CD45 (p = 0.0001) and CD20 (p = 0.0004). Lower levels of BCL2 expression were noted in the BCL6(+)/MYC(+) and BCL2(+)/BCL6(+)/MYC(+) subgroups versus BCL2(+)/MYC(+) cases (p = 0.0014). Of the flow cytometric parameters assessed, dim CD45 expression correlated with inferior survival (p = 0.01). Although there is some overlap with B-LBL, D/THL demonstrates a characteristic immunophenotype which may have prognostic significance and warrants further investigation.

show abstract

Section: Discussionsupporting

confidence: 90%

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma

Roth

Gillespie-Twardy²,

Marks³

et al. 2016

oncol res

View full text Add to dashboard Cite

show abstract

“…Accurate identification of DHL, so that appropriate management can be started, is therefore important (Friedberg, 2017). Major FC and pathology studies have reported that the immunophenotype of cells in DHL is characterized by high levels of CD10, CD38, BCL2, CD43, and Ki-67, as well as decreased amounts of CD19 and CD20 (Alsuwaidan et al, 2019;Cordoba et al, 2016;Platt, DeLelys, Preffer, et al, 2013;Wu et al, 2010). Our results show that the isolated evaluation of CD20 median fluorescence intensity, CD38% expression and median fluorescence intensity, CD45 intensity, Ki-67% expression, bcl-2% expression, CD10% expression, and CD43% expression cannot be used to differentiate DHL from BL or MYC-DLBCL.…”

Section: Discussionmentioning

confidence: 99%

Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma

Tsagarakis

Papadhimitriou

Pavlidis

et al. 2020

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background There are no immunophenotypic guidelines for the investigation of MYC‐rearranged lymphomas. We aimed to identify simple immunophenotypic features that would help to differentiate between MYC‐rearranged lymphomas and guide cytogenetic analysis. Methods We reviewed diagnostic samples from patients diagnosed with Burkitt lymphoma (BL), double‐hit lymphoma (DHL), MYC‐rearranged diffuse large B‐cell lymphoma (MYC‐DLBCL), and standard (non‐MYC‐rearranged) DLBCL over the last decade in our Institution. Using flow cytometry (with antibodies CD20, CD10, CD38, bcl‐2, Ki‐67, FMC‐7, CD43, CD27, CD79b, CD23, and CD22) we determined antigen% expression and median‐fluorescence intensity ratios (MFIR). The forward scatter (FS) and side scatter (SS) characteristics of tumor B‐cells were compared with normal T‐cells (B/T ratios) for patients with MYC‐rearranged lymphomas. Results We identified 51 patients of whom 14 had BL, 10 had DHL (6 MYC+/BCL2+; 4 MYC+/BCL6+), 8 MYC‐DLBCL, and 19 standard DLBCL. The significant differences (p <.05) were: higher CD38% in BL than standard DLBCL; higher CD10% in BL and DHL versus MYC‐DLBCL and standard DLBCL; higher CD10MFIR in BL than MYC‐DLBCL and standard DLBCL; higher Ki‐67% in BL than DHL and MYC‐DLBCL; higher bcl‐2% in DHL than BL; higher FMC‐7% in BL than MYC‐DLBCL and standard DLBCL; and lower SS (B/T) ratio in DHL than MYC‐DLBCL. Conclusions The combination of CD38% > 90, CD10% > 80, CD10MFIR > 10, bcl‐2% < 30, and Ki‐67% > 70 was characteristic of BL. “Deviation” from these cut‐offs should raise suspicion for DHL and, therefore, BCL2 and/or BCL6 FISH is required. We also found that a diagnosis of DHL rather than of MYC‐DLBCL was significantly associated with CD10% > 60, Ki‐67% > 50, and SS (B/T) <1.5.

show abstract

“…The high sensitivity of this technique allows for its application even with limited samples, particularly in challenging scenarios where accessing lymph nodes is impractical. This was demonstrated in another case where FCM immunophenotyping of ascitic fluid detected a DHL in a relapsed DLBCL patient [179]. Moreover, evaluating early therapy response via FCM proved valuable in predicting outcome and optimizing the treatment strategy for a patient with primary BM B cell lymphoma [180].…”

Section: Case Studies Using Proteomicsmentioning

confidence: 94%

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Jiménez,

Garrote-de-Barros,

López-Portugués

et al. 2024

IJMS

View full text Add to dashboard Cite

The maturation of B cells is a complex, multi-step process. During B cell differentiation, errors can occur, leading to the emergence of aberrant versions of B cells that, finally, constitute a malignant tumor. These B cell malignancies are classified into three main groups: leukemias, myelomas, and lymphomas, the latter being the most heterogeneous type. Since their discovery, multiple biological studies have been performed to characterize these diseases, aiming to define their specific features and determine potential biomarkers for diagnosis, stratification, and prognosis. The rise of advanced -omics approaches has significantly contributed to this end. Notably, proteomics strategies appear as promising tools to comprehensively profile the final molecular effector of these cells. In this narrative review, we first introduce the main B cell malignancies together with the most relevant proteomics approaches. Then, we describe the core studies conducted in the field and their main findings and, finally, we evaluate the advantages and drawbacks of flow cytometry, mass cytometry, and mass spectrometry for the profiling of human B cell disorders.

show abstract

The utility of multiparametric seven‐color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples

Cited by 9 publications

References 4 publications

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma

Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Contact Info

Product

Resources

About